Roman Gulati wrote an editorial for the New England Journal of Medicine on the GÖTEBORG-2 trial.
The seven-year, $7.4M Outstanding Investigator Award (OIA) from the National Cancer Institute will will provide long-term support for Ruth's work to investigate accuracy of multi-cancer liquid biopsies and other new technology. Details here.
A biostatistician, a disease modeler, a cancer epidemiologist, a computer programmer, a policy researcher, and now a Lab Elder. Congratulations and thanks, Roman! Your contributions cannot be overstated.
A study my colleagues and I published March 1 in the Annals of Internal Medicine offers a new estimate of the extent of overdiagnosis in contemporary U.S. practice and concludes that it might not be as frequent as we thought.